Influence of biosimilar infliximab launch on the utilization pattern of biological medicines : the case of Hungary
| Autor: | Marcell Csanádi, Kristóf Márky, Zoltán Kaló, Áron Zoltán Vincziczki, András Inotai, András Harsányi |
|---|---|
| Přispěvatelé: | Gyógyszertudomány Doktori Iskola, Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet, PhD Szociológia Doktori Iskola, Gyógyszerészeti Intézet, Egészségügyi Technológiaértékelő és Elemzési Központ, Egészségpolitikai és Egészség-gazdaságtan Tanszék |
| Rok vydání: | 2019 |
| Předmět: |
Drug Utilization
medicine.medical_specialty Health outcomes Health Services Accessibility Resource Allocation Competition (economics) Patents as Topic 03 medical and health sciences Monopolistic competition 0302 clinical medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Longitudinal Studies Intensive care medicine Initial therapy Biosimilar Pharmaceuticals Retrospective Studies Biological Products Hungary Drug Substitution 030503 health policy & services Health Policy Biosimilar General Medicine Infliximab Insurance Health Reimbursement Business 0305 other medical science Previously treated medicine.drug |
| Zdroj: | EXPERT REV PHARMACOECON OUTCOMES RES EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH IN PRESS. |
| Popis: | Objectives: Utilization of multisource biological (off-patent originator and its biosimilar) medicines can improve the efficiency of resource allocation by 1) generating savings while maintaining health outcomes or 2) increasing the number of patients treated with more affordable treatments. This study evaluates the efficiency of the Hungarian biosimilar drug policy on the case of biosimilar infliximab. Methods: We analyzed the utilization of biologicals in all reimbursed indications of infliximab including initial therapy of new patients and switching patterns retrospectively based on patient-level payer's data between September 2012 and December 2016. Results: Despite the economic rationale, patent expiry did not manifest in increased utilization of multisource infliximab in an access-restricted environment: 1) Patients previously treated with original biologicals were switched mainly to other original biologicals instead of more affordable biosimilar alternatives. 2) Although some treatment-naive patients started on more affordable multisource infliximab with price competition, the majority of new patients started on other original biologicals with monopolistic price. Conclusion: Policy tools and measures should be developed to facilitate first-line use of multisource biologicals for treatment-naive patients and promoting the use of more affordable multisource biologicals in case of switching. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|